PMVP
NASDAQPMV Pharmaceuticals Inc.
PMV Pharmaceuticals Inc. (PMVP) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. In the last 30 days Quantisnow tracked 3 wire items for PMVP, including 2 SEC filings and 1 earnings update. The most recent was published Nov 10, 2026.
PMVP rankings
Financial highlights
Full financials- Net income, TTM
- -$88.53M
- Free cash flow, TTM
- -$69.64M
- Cash
- $19.99M
For the twelve months ended Sep 30, 2026, from SEC filings. Not investment advice.
News · 26 weeks26-25%
2026-05-172026-11-08
Mix1790d
- SEC Filings8(47%)
- Other2(12%)
- Offering2(12%)
- Leadership2(12%)
- Insider2(12%)
- Earnings1(6%)
Activity · 52 weeks4520 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Latest news
25 items- SECSEC Form 10-Q filed by PMV Pharmaceuticals Inc.10-Q - PMV Pharmaceuticals, Inc. (0001699382) (Filer)
- SECPMV Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - PMV Pharmaceuticals, Inc. (0001699382) (Filer)
- PRPMV Pharmaceuticals Reports Third Quarter 2026 Financial Results and Corporate HighlightsPivotal Phase 2 rezatapopt PYNNACLE data to be featured in late-breaking oral presentation at ENA 2026Announced closing of oversubscribed $50 million public offering of securitiesRezatapopt NDA submission for platinum-resistant/refractory ovarian cancer planned in first quarter of 2027Cash, cash equivalents, and marketable securities of $108.5 million as of September 30, 2026 providing expected cash runway into first quarter of 2028 PRINCETON, N.J., Nov. 10, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (("PMV Pharma" or the "Company", NASDAQ:PMVP), a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53, today reported fina
- INSIDERSEC Form 4 filed by PMV Pharmaceuticals Inc.4 - PMV Pharmaceuticals, Inc. (0001699382) (Issuer)
- INSIDERSEC Form 3 filed by PMV Pharmaceuticals Inc.3 - PMV Pharmaceuticals, Inc. (0001699382) (Issuer)
- SECPMV Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - PMV Pharmaceuticals, Inc. (0001699382) (Filer)
- PRPMV Pharmaceuticals Appoints Matt Eckler, Ph.D., to Board of DirectorsDr. Eckler brings more than two decades of combined experience in healthcare investing across public and private markets at Samsara BioCapital, ArrowMark, and GMT Capital, and scientific research Company planning NDA submission for accelerated approval of rezatapopt in patients with platinum-resistant/refractory ovarian cancer in first quarter of 2027 PRINCETON, N.J., Oct. 05, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (("PMV Pharma" or the "Company", NASDAQ:PMVP), a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53, today announced the appointment of Matt Eckler, Ph.D., to its Board of Directors (the "Board"). Dr. Eckl
- PRPMV Pharmaceuticals Appoints Philip Herman as Chief Commercial OfficerCommercial leadership appointment supports launch preparation for rezatapopt Company planning NDA submission for accelerated approval of rezatapopt in patients with platinum-resistant/refractory ovarian cancer in first quarter of 2027 PRINCETON, N.J., Sept. 08, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (("PMV Pharma" or the "Company", NASDAQ:PMVP), a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53, today announced the appointment of Philip Herman as Chief Commercial Officer (CCO). Mr. Herman will lead the Company’s commercial strategy and launch preparation for rezatapopt, PMV Pharma’s first-in-class p53 reactivator.
- PRPMV Pharma Announces Pricing of Oversubscribed $50 Million Public Offering of SecuritiesPRINCETON, N.J., Aug. 31, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (("PMV Pharma" or the "Company", NASDAQ:PMVP), a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53, announced today the pricing of an underwritten public offering consisting of (i) 22,055,000 shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase an aggregate of up to 19,900,000 shares of its common stock, and (ii) accompanying warrants to purchase an aggregate of 41,955,000 shares of common stock. The common stock and pre-funded warrants are being sold in combination with an accompanying warrant to p
- SECSEC Form 424B3 filed by PMV Pharmaceuticals Inc.424B3 - PMV Pharmaceuticals, Inc. (0001699382) (Filer)
- SECSEC Form 424B5 filed by PMV Pharmaceuticals Inc.424B5 - PMV Pharmaceuticals, Inc. (0001699382) (Filer)
- SECSEC Form 8-K filed by PMV Pharmaceuticals Inc.8-K - PMV Pharmaceuticals, Inc. (0001699382) (Filer)
- PRPMV Pharma Announces Proposed Public Offering of SecuritiesPRINCETON, N.J., Aug. 31, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (("PMV Pharma" or the "Company", NASDAQ:PMVP), a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53, announced today that it has commenced an underwritten public offering of shares of its common stock and accompanying warrants to purchase shares of its common stock and, in lieu of common stock, to certain investors, pre-funded warrants to purchase shares of its common stock and accompanying warrants to purchase shares of its common stock. All of the shares, pre-funded warrants and accompanying common stock warrants to be sold in the proposed offering are t
- PRPMV Pharmaceuticals Announces Updated Promising Rezatapopt Monotherapy Interim Ovarian Cancer Data From PYNNACLE Phase 2 Pivotal Trial46% ORR observed among 76 evaluable patients in the ovarian cancer cohort with a median duration of response of 10.0 monthsRecent FDA interaction supports NDA submission strategy for accelerated approval of rezatapopt for platinum-resistant/refractory ovarian cancer, with submission planned in first quarter of 2027PMV plans to provide an update on all PYNNACLE Phase 2 pivotal trial cohorts at a medical conference in fourth quarter of 2026 PRINCETON, N.J., Aug. 31, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (("PMV Pharma" or the "Company", NASDAQ:PMVP), a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53, today announced u
- SECSEC Form 10-Q filed by PMV Pharmaceuticals Inc.10-Q - PMV Pharmaceuticals, Inc. (0001699382) (Filer)
- SECPMV Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - PMV Pharmaceuticals, Inc. (0001699382) (Filer)
- PRPMV Pharmaceuticals Reports Second Quarter 2026 Financial Results and Corporate HighlightsEnrollment of platinum-resistant/refractory ovarian cancer patients for the primary analysis in the Phase 2 monotherapy portion of the PYNNACLE clinical trial completedRezatapopt NDA submission for platinum-resistant/refractory ovarian cancer planned in first quarter of 2027Cash, cash equivalents, and marketable securities of $79.4 million as of June 30, 2026 providing expected cash runway through second quarter of 2027 PRINCETON, N.J., Aug. 14, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (("PMV Pharma" or the "Company", NASDAQ:PMVP), a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53, today reported financial results for
- SECAmendment: SEC Form SCHEDULE 13G/A filed by PMV Pharmaceuticals Inc.SCHEDULE 13G/A - PMV Pharmaceuticals, Inc. (0001699382) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by PMV Pharmaceuticals Inc.SCHEDULE 13G/A - PMV Pharmaceuticals, Inc. (0001699382) (Subject)
- ANALYSTLadenburg Thalmann initiated coverage on PMV Pharmaceuticals with a new price targetLadenburg Thalmann initiated coverage of PMV Pharmaceuticals with a rating of Buy and set a new price target of $3.00
- INSIDERSEC Form 4 filed by Director Stelzer Laurie4 - PMV Pharmaceuticals, Inc. (0001699382) (Issuer)
- INSIDERSEC Form 4 filed by Director Levine Arnold J4 - PMV Pharmaceuticals, Inc. (0001699382) (Issuer)
- INSIDERSEC Form 4 filed by Director Gallagher Carol Giltner4 - PMV Pharmaceuticals, Inc. (0001699382) (Issuer)
- INSIDERSEC Form 4 filed by Director Flowers Kirsten4 - PMV Pharmaceuticals, Inc. (0001699382) (Issuer)
- INSIDERSEC Form 4 filed by Director Baum Charles M4 - PMV Pharmaceuticals, Inc. (0001699382) (Issuer)
PMVP FAQ
10 questionsWhat does PMV Pharmaceuticals Inc. do?
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule, tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects a p53 protein containing the Y220C mutation and restores p53 function. It is also developing p53 R273H mutation and other p53 hotspot mutations. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in...What is the latest news on PMVP?
In the last 30 days Quantisnow tracked 3 wire items for PMVP: 2 SEC filings and 1 earnings update. The most recent was published on November 10, 2026.Is PMVP profitable?
No. PMV Pharmaceuticals Inc. reported a net loss of $88.53M for the twelve months ended Sep 30, 2026.How much cash and debt does PMVP have?
PMV Pharmaceuticals Inc. reported $19.99M in cash and cash equivalents on its most recent balance sheet in SEC filings.Where does PMVP stock trade?
PMV Pharmaceuticals Inc. (PMVP) is listed on NASDAQ.What sector and industry is PMVP in?
PMV Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did PMV Pharmaceuticals Inc. go public?
PMV Pharmaceuticals Inc. (PMVP) completed its IPO in 2020.What are analysts saying about PMVP?
Across the last 8 analyst actions on PMV Pharmaceuticals Inc., there were 4 upgrades and 0 downgrades. The most recent action was from Ladenburg Thalmann: Buy with a $3.00 price target on 2026-07-08.What companies are similar to PMVP?
Notable peers in the same industry include ZNTL (Zentalis Pharmaceuticals Inc.), CGEM (Cullinan Therapeutics Inc.), RVMD (Revolution Medicines Inc.), ERAS (Erasca Inc.), RAIN (Rain Enhancement Technologies Holdco Inc.). Compare PMVP side-by-side with any of them on Quantisnow.How can I track PMVP on Quantisnow?
Quantisnow aggregates PMV Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow PMVP to receive live email and push alerts on every new disclosure.